FDA approves updated label for Unloxcyt
by Lori Solomon edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The updated label incorporates long-term […]
FDA approves updated label for Unloxcyt Read More »
